[1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics 2014. CA Cancer J Clin, 2014; 64: 252-71.10.3322/caac.2123524890451]Search in Google Scholar
[2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.]Search in Google Scholar
[3. National Cancer Institute. Small cell lung cancer treatment. [citated 2015 Jan 15]. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional/page1/AllPages#Section_267. 2014.]Search in Google Scholar
[4. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-24.10.1056/NEJM1992120332723021331787]Search in Google Scholar
[5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-5.10.1200/JCO.1992.10.6.8901316951]Search in Google Scholar
[6. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-67.10.1200/JCO.1999.17.2.65810080612]Search in Google Scholar
[7. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-7.10.1200/JCO.2006.06.582117135646]Search in Google Scholar
[8. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25: 2086-92.10.1200/JCO.2006.08.399817513814]Search in Google Scholar
[9. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-9.10.1093/jnci/djp369413723219903805]Search in Google Scholar
[10. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21: 2324-32.]Search in Google Scholar
[11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.10.1200/JCO.2007.14.546619188680]Search in Google Scholar
[12. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PloS one 2011; 6: e26646.10.1371/journal.pone.0026646321963322114662]Search in Google Scholar
[13. Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537-41.10.1093/annonc/mdr48722039091]Search in Google Scholar
[14. Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med 2015; 10: 61-6.]Search in Google Scholar
[15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.205]Search in Google Scholar
[16. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264-70.10.1200/JCO.1988.6.8.1264]Search in Google Scholar
[17. Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997; 27: 166-9.10.1093/jjco/27.3.166]Search in Google Scholar
[18. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-6.10.1016/S1470-2045(06)70800-2]Search in Google Scholar
[19. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-7.10.1097/JTO.0b013e3181989bd219190515]Search in Google Scholar
[20. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117: 1262-71.10.1002/cncr.25526302526720960500]Search in Google Scholar
[21. Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Post progression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer 2013; 14: 261-6.10.1016/j.cllc.2012.09.00623107465]Search in Google Scholar
[22. Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma 2014; 61: 233-40.10.4149/neo_2014_03024299320]Search in Google Scholar